THE ERA OF MULTI-CANCER EARLY DETECTION IS JUST BEGINNING
Our goal is to fulfill its promise.
The upper hand against cancer
There is a moment when we all have the upper hand against cancer. It’s before the first signs and symptoms show up, when more options are on the table. But too often, early detection opportunities are unavailable or missed.1 Today, we only have routine screening tests for about one-third of diagnosed cancers.2* This means that many cancers go undetected until it’s too late.1
Our vision for the Cancerguard™ test aims to transform cancer screening.
*Calculated using estimated new diagnoses and deaths from cancers that have standard-of-care screening: breast, cervical, colorectal, and lung (high risk) against all sites.
We are developing the multi-cancer early detection (MCED) test of the future—the Cancerguard™ test
The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.
References
- Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; doi:10.3322/caac.21820
- Douville C, Nobles C, Hwang HJ, et al. Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Poster presented at: ESMO Congress; September 9-13, 2022; Paris, France. Abstract 73P.